Details of the Drug

General Information of Drug (ID: DMKUOQV)

• Drug Name: Burosumab
• Synonyms: Burosumab [USAN]; UNII-G9WJT6RD29; G9WJT6RD29

Indication

Disease Entry	ICD 11	Status	REF
X-linked hypophosphataemia	5C63.22	Approved	[1]

• Affected Organisms: Humans and other mammals
• ATC Code:
  M05BX05: Burosumab
  M05BX: Other drugs affecting bone structure and mineralization
  M05B: DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
  M05: DRUGS FOR TREATMENT OF BONE DISEASES
  M: MUSCULO-SKELETAL SYSTEM
• Drug Type: Antibody
• Sequence:
  >heavy chain
  QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHYMHWVRQAPGQGLEWMGIINPISGSTSN
  AQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDIVDAFDFWGQGTMVTVSSAST
  KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
  SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV
  FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
  RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK
  NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG
  NVFSCSVMHEALHNHYTQKSLSLSPGK
  >light chain
  AIQLTQSPSSLSASVGDRVTITCRASQGISSALVWYQQKPGKAPKLLIYDASSLESGVPS
  RFSGSGSGTDFTLTISSLQPEDFATYYCQQFNDYFTFGPGTKVDIKRTVAAPSVFIFPPS
  DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL
  SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 5-10 days [2]
  Clearance: The clearance of drug is 0.290 L/day [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 19 days [2]
  Metabolism: The drug is metabolized via the hepatic metabolic mechanisms [2]
• Cross-matching ID:
  UNII: G9WJT6RD29
  DrugBank ID: DB14012
  TTD ID: D0DJ9D

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor-23 (FGF23)	TT2IZ4K	FGF23_HUMAN	Modulator	[1]

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] Crysvita Drug Label